S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Sell every Stock except ONE (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Sell every Stock except ONE (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Sell every Stock except ONE (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Sell every Stock except ONE (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:CTIC

CTI BioPharma - CTIC Price Target & Analyst Ratings

$5.83
+0.42 (+7.76%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.26
$5.86
50-Day Range
$5.16
$7.43
52-Week Range
$1.43
$7.80
Volume
5.49 million shs
Average Volume
4.74 million shs
Market Capitalization
$666.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.33

CTI BioPharma Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$10.33
77.24% Upside
High Prediction$12.00
Average Prediction$10.33
Low Prediction$9.00
TypeCurrent
8/18/21 to 8/18/22
1 Month Ago
7/19/21 to 7/19/22
3 Months Ago
5/20/21 to 5/20/22
1 Year Ago
8/18/20 to 8/18/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.33$9.29$9.83$7.42
Predicted Upside77.24% Upside108.60% Upside247.26% Upside186.36% Upside
Get CTI BioPharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.


CTIC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CTIC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CTI BioPharma Stock vs. The Competition

TypeCTI BioPharmaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.70
2.50
Consensus RatingBuyBuyHold
Predicted Upside77.24% Upside881.43% Upside14.53% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
277
64.72%
Underperform Votes
151
35.28%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
854
68.59%
Avg. Underperform Votes
391
31.41%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/9/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gil Blum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$8.00 ➝ $9.00+42.63%
8/9/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reni Benjamin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Outperform$6.00 ➝ $9.00+35.54%
7/7/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$10.00+66.67%
3/1/2022Brookline Capital Acquisition
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$7.20 ➝ $12.00+334.78%
3/1/2022Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Cann
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$7.20 ➝ $12.00+344.44%
8/9/2021BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$7.00+150.00%
6/1/2021Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$13.00 ➝ $15.00+492.88%
5/6/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$5.50+135.04%
(Data available from 8/18/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CTIC Price Target - Frequently Asked Questions

What is CTI BioPharma's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for CTI BioPharma stock is Buy based on the current 6 buy ratings for CTIC. The average twelve-month price prediction for CTI BioPharma is $10.33 with a high price target of $12.00 and a low price target of $9.00. Learn more on CTIC's analyst rating history.

Do Wall Street analysts like CTI BioPharma more than its competitors?

Analysts like CTI BioPharma more than other Medical companies. The consensus rating score for CTI BioPharma is 3.00 while the average consensus rating score for medical companies is 2.70. Learn more on how CTIC compares to other companies.

Do MarketBeat users like CTI BioPharma more than its competitors?

MarketBeat users like CTI BioPharma less than other Medical companies. 64.72% of MarketBeat users gave CTI BioPharma an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does CTI BioPharma's stock price have much upside?

According to analysts, CTI BioPharma's stock has a predicted upside of 103.88% based on their 12-month price targets.

What analysts cover CTI BioPharma?

CTI BioPharma has been rated by Cowen, Cowen, JMP Securities, and Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CTIC) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.